- Home
- ATRA vs CLSD Comparison
ATRA vs CLSD Comparison
Compare ATRA & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- CLSD
- Stock Information
- Founded
- ATRA 2012
- CLSD 2011
- Country
- ATRA United States
- CLSD United States
- Employees
- ATRA N/A
- CLSD N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- CLSD Health Care
- Exchange
- ATRA Nasdaq
- CLSD Nasdaq
- Market Cap
- ATRA 67.9M
- CLSD 68.4M
- IPO Year
- ATRA 2014
- CLSD 2016
- Fundamental
- Price
- ATRA $12.29
- CLSD $0.42
- Analyst Decision
- ATRA Strong Buy
- CLSD Hold
- Analyst Count
- ATRA 3
- CLSD 4
- Target Price
- ATRA $21.00
- CLSD $4.33
- AVG Volume (30 Days)
- ATRA 65.3K
- CLSD 12.9M
- Earning Date
- ATRA 08-11-2025
- CLSD 08-08-2025
- Dividend Yield
- ATRA N/A
- CLSD N/A
- EPS Growth
- ATRA N/A
- CLSD N/A
- EPS
- ATRA 0.56
- CLSD N/A
- Revenue
- ATRA $188,667,000.00
- CLSD $4,166,000.00
- Revenue This Year
- ATRA N/A
- CLSD $78.37
- Revenue Next Year
- ATRA N/A
- CLSD $17.79
- P/E Ratio
- ATRA $21.82
- CLSD N/A
- Revenue Growth
- ATRA 202.41
- CLSD N/A
- 52 Week Low
- ATRA $5.01
- CLSD $0.29
- 52 Week High
- ATRA $18.71
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- ATRA 62.30
- CLSD 39.95
- Support Level
- ATRA $10.32
- CLSD $0.40
- Resistance Level
- ATRA $12.31
- CLSD $0.47
- Average True Range (ATR)
- ATRA 0.90
- CLSD 0.06
- MACD
- ATRA -0.04
- CLSD 0.01
- Stochastic Oscillator
- ATRA 77.93
- CLSD 26.87
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.